Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
View Patent ↗The present invention relates to the antagonism of the effects of melanin-concentrating hormone (MCH) through the melanin concentrating hormone receptor which is useful for the prevention or treatment of eating disorders, weight gain, obesity, abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping, arousal, anxiety, depression, seizures, neurodegeneration and psychiatric disorders.
1. A compound of formula (I),
or a therapeutically suitable salt or prodrug thereof, wherein
A is selected from the group consisting of —C(O)—, —S(O)—, —S(O) 2 —, —C(═NR a )— and —C(═S)—;
B is selected from the group consisting of alkylene, alkenyl, carbonylalkyl, cycloalkyl, —NR b — and —NR b -alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-C(O)—NH—, alkyl-NH—, alkyl-NH—C(O)—, alkyl-NH—S(O) 2 —, alkoxy, alkyl-S—, alkyl-S(O) 2 —, alkyl-S(O) 2 —NH—, aryl, aryl-C(O)—, aryl-C(O)—NH—, aryl-C═N—O—, aryl-NH—, aryl-NH—C(O)—, aryl-NH—S(O) 2 —, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, aryl-S(O) 2 —, aryl-S(O) 2 —NH—, arylalkyl-C(O)—, arylalkyl-C(O)—NH—, arylalkyl-NH—, arylalkyl-NH—C(O)—, arylalkyl-NH—S(O) 2 —, arylalkoxy, arylalkyl-S—, arylalkyl-S(O) 2 —, arylalkyl-S(O) 2 —NH—, cycloalkyl, cycloalkyl-C(O)—, cycloalkyl-C(O)—NH—, cycloalkyl-NH—, cycloalkyl-NH—C(O)—, cycloalkyl-NH—S(O) 2 —, cycloalkoxy, cycloalkyl-S—, cycloalkyl-S(O) 2 —, cycloalkyl-S(O) 2 —NH—, cycloalkenyl, cycloalkenylalkyl, cycloalkenyl-C(O)—, cycloalkenyl-C(O)—NH—, cycloalkenyl-NH—, cycloalkenyl-NH—C(O)—, cycloalkenyl-NH—S(O) 2 —, cycloalkenyloxy, cycloalkenyl-S—, cycloalkenyl-S(O) 2 —, cycloalkenyl-S(O) 2 —NH—, heterocycle, heterocycle-C(O)—, heterocycle-C(O)—NH—, heterocycle-NH—, heterocycle-NH—C(O)—, heterocycle-NH—S(O) 2 —, heterocycle-O—, heterocycle-S—, heterocycle-S(O) 2 —, heterocycle-S(O) 2 —NH—, heterocyclealkyl-C(O)—, heterocyclealkyl-C(O)—NH—, heterocyclealkyl-NH—, heterocyclealkyl-NH—C(O)—, heterocyclealkyl-NH—S(O) 2 —, heterocyclealkyl-O—, heterocyclealkyl-S—, heterocyclealkyl-S(O) 2 — and heterocyclealkyl-S(O) 2 —NH—,
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R a is selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, heterocycle, heterocyclealkyl and hydroxyalkyl, or R c and R d taken together with any intervening atoms form a heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b - or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; and if A is C(O), B is NR b , D is aryl, m=1, Z is H, R 1 is H, R 4 is H, R 2 is H, and R c and R d are alkyl, then E cannot be heteroaryl-O.
2. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, alkyl-S(O) 2 —, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, aryl-S(O) 2 —, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, arylalkyl-S(O) 2 —, cycloalkyl, cycloalkyl-C(O)—, cycloalkyl-NH—, cycloalkoxy, cycloalkyl-S(O) 2 —, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocycle-S(O) 2 —, heterocyclealkyl-C(O)—, heterocyclealkyl-NH—, heterocyclealkyl-O— and heterocyclealkyl-S(O) 2 —;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R a is selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, heterocycle, heterocyclealkyl and hydroxyalkyl, or R c and R d taken together with any interveneing atoms form a heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; and if A is C(O), B is NR b , D is aryl, m=1, Z is H, R 1 is H, R 4 is H, R 2 is H, and R c and R d are alkyl, then E cannot be heteroaryl-O.
3. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH— and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R a is selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, heterocycle, heterocyclealkyl and hydroxyalkyl; or R c and R d taken together with any intervening atoms form a heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; and if A is C(O), B is NR b , D is aryl, m=1, Z is H, R 1 is H, R 4 is H, R 2 is H, and R c and R d are alkyl, then E cannot be heteroaryl-O.
4. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R a is selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d are each independently selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkenylalkyl, heterocycle, heterocyclealkyl and hydroxyalkyl;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl; and if A is C(O), B is NR b , D is aryl, m=1, Z is H, R 1 is H, R 4 is H, R 2 is H, and R c and R d are alkyl, then E cannot be heteroaryl-O.
5. The compound according to claim 4 , wherein the compound is selected from the group consisting of
N-[1-(2-dimethylamino-ethyl)-1H-indazol-4-yl]-2-(4-phenoxy-phenyl)-acetamide;
N-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-2-(4-phenoxy-phenyl)-acetamide;
1-[1-(2-dimethylamino-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea;
N-{1-[2-(diethylamino)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-(1-{2-[isobutyl(methyl)amino]ethyl}-1H-indazol-5-yl)-N′-(4-phenoxyphenyl)urea;
N-(1-{2-[isopropyl(methyl)amino]ethyl}-1H-indazol-5-yl)-N′-(4-phenoxyphenyl)urea;
N-[1-(2-dimethylamino-ethyl)-1H-indazol-6-yl]-2-(4-phenoxy-phenyl)-acetamide;
2-(4-benzyloxy-phenyl)-N-[1-(2-dimethylamino-ethyl)-1H-indazol-6-yl]-acetamide;
N-{1-[2-(cyclopentylamino)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-(1-{2-[(2-morpholin-4-ylethyl)amino]ethyl}-1H-indazol-6-yl)-2-(4-phenoxyphenyl)acetamide;
2-(4-phenoxyphenyl)-N-(1-{2-[(tetrahydrofuran-2-ylmethyl)amino]ethyl}-1H-indazol-6-yl)acetamide;
N-(1-{2-[(2-cyclohex-1-en-1-ylethyl)amino]ethyl}-1H-indazol-6-yl)-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(diisopropylamino)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(cyclopentylamino)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-(1-{3-[cyclohexyl(methyl)amino]propyl}-1H-indazol-6-yl)-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(diisobutylamino)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide; and
2-[4-(benzyloxy)phenyl]-N-[1-(3-dimethylamino-propyl)-1H-indazol-6-yl]acetamide.
6. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form a 4 membered heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
7. The compound according to claim 1 that is
N-[1-(2-azetidin-1-ylethyl)-1H-indazol-5-yl]-N′-(4-phenoxyphenyl)urea.
8. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form a 5 membered heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
9. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form
Y is selected from the group consisting of —O—, —NR j —, —CHR j — and —C(O)—;
Z is selected from the group consisting of hydrogen, alkyl and halogen;
R 8 is selected from the group consisting of hydrogen and alkyl;
R 9 and R 10 are each individually selected from the group consisting of oxo, hydrogen and alkyl; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
10. The compound according to claim 9 , wherein the compound is selected from the group consisting of
N-(2-oxo-2-{[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]amino}ethyl)-4-phenoxybenzamide;
2-[(4-phenoxybenzyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-[4-(benzyloxy)phenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-(3-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
3-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]propanamide;
2-{4-[(2,3-difluorobenzyl)oxy]phenyl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-[4-(benzyloxy)phenyl]-N-(1-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-1H-indazol-4-yl)acetamide;
2-[4-(benzyloxy)phenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]acetamide;
3-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]propanamide;
2-(3-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]acetamide;
4-(4-chlorophenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]cyclohexanecarboxamide;
3-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]propanamide;
2-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]acetamide;
(2E)-3-(1,1′-biphenyl-4-yl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]acrylamide;
N-(4-phenoxyphenyl)-N′-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea;
N-(5-phenylthien-2-yl)-N′-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]urea;
1-(4-phenylamino-phenyl)-3-[1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-yl]-urea;
N-{1-[2-(2-methylpyrrolidin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-(1-{2-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-5-yl)-N′-(4-phenoxyphenyl)urea;
N-(1-{2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]ethyl}-1H-indazol-5-yl)-N′-(4-phenoxyphenyl)urea;
N-{1-[2-(2,3-dihydro-1H-indol-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-((3R)-1-{2-[5-({[(4-phenoxyphenyl)amino]carbonyl}amino)-1H-indazol-1-yl]ethyl}pyrrolidin-3-yl)acetamide;
N-{1-[2-(3-hydroxypyrrolidin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
2-[4-(benzyloxy)phenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-(3-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
4-(1,1′-biphenyl-4-yl)-4-oxo-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]butanamide;
3-(2-naphthylthio)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
2-(5-{[(4-methylphenyl)thio]acetyl}thien-2-yl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
3-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
3-[5-(4-methylphenyl)-1,3-oxazol-2-yl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
2-[4-(benzyloxy)-3-methoxyphenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
3-[4-(benzyloxy)-3-methoxyphenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
2-(4-phenoxyphenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
3-[4-(benzyloxy)phenyl]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
3-(4-phenoxypyridin-3-yl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
2-{4-[(4-fluorobenzyl)oxy]phenyl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-{4-[(3-fluorobenzyl)oxy]phenyl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-(4-{[4-(difluoromethoxy)benzyl]oxy}phenyl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-{4-[(3,5-dichlorobenzyl)oxy]phenyl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-{4-[(3-cyanobenzyl)oxy]phenyl}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
N-[2-(4-phenoxyphenyl)ethyl]-N′-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]urea;
N-(4-phenoxybenzyl)-N′-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]urea;
N-[4-(benzyloxy)phenyl]-N′-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]urea;
2-(3′-acetyl-1,1′-biphenyl-4-yl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]-2-[4′-(trifluoromethoxy)-1,1′-biphenyl-4-yl]acetamide;
2-(4′-fluoro-1,1′-biphenyl-4-yl)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
3-[(1,1′-biphenyl-4-ylmethyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
3-[(3-phenoxybenzyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]propanamide;
N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]-3-[(4-thien-2-ylbenzyl)amino]propanamide;
2-[(4-phenoxybenzyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-{[(6-methoxy-2-naphthyl)methyl]amino}-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-[(1,1′-biphenyl-4-ylmethyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-[(3-phenoxybenzyl)amino]-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
2-({[5-(2-chlorophenyl)-2-furyl]methyl}amino)-N-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
N-{1-[2-(2,5-dimethylpyrrolidin-1-yl)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[2-(2-methylpyrrolidin-1-yl)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
2-(4-phenoxyphenyl)-N-[1-(3-pyrrolidin-1-ylpropyl)-1H-indazol-6-yl]acetamide;
N-(1-{3-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]propyl}-1H-indazol-6-yl)-2-(4-phenoxyphenyl)acetamide;
N-(1-{3-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]propyl}-1H-indazol-6-yl)-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(2-methylpyrrolidin-1-yl)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
2-[4-(benzyloxy)phenyl]-N-{1-[2-(2-oxo-1,3-oxazolidin-3-yl)ethyl]-1H-indazol-6-yl}acetamide;
2-[4-(benzyloxy)phenyl]-N-{1-[2-(2-oxopyrrolidin-1-yl)ethyl]-1H-indazol-6-yl}acetamide;
2-[4-(benzyloxy)phenyl]-N-{1-[2-(2,5-dioxopyrrolidin-1-yl)ethyl]-1H-indazol-6-yl}acetamide;
2-[4-(benzyloxy)phenyl]-N-[3-chloro-1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
N-[3-chloro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-4-yl]-2-(4-phenoxy-phenyl)acetamide;
2-[4-(benzyloxy)phenyl]-N-[3-bromo-1-(2-pyrrolidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
1-[3-chloro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)urea;
1-[3-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)urea;
N-[3-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-5-yl]-2-(4-phenoxy-phenyl)acetamide;
N-[3-chloro-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]-2-(4-phenoxy-phenyl)acetamide;
2-[4-(benzyloxy)phenyl]-N-[3-bromo-1-(2-pyrrolidin-1-ylethyl)-1H-indazol-6-yl]acetamide;
N-[3-bromo-1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]-2-(4-phenoxy-phenyl)acetamide;
1-(4-phenoxyphenyl)-3-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]-1,3-dihydro-2H-imidazol-2-one; and
1-(4-phenoxyphenyl)-3-[1-(2-pyrrolidin-1-ylethyl)-1H-indazol-5-yl]imidazolidin-2-one.
11. The compound according to claim 1 wherein
A is —C(O)—;
B or is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form a 6 membered heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
12. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form
Y is selected from the group consisting of —O—, —NR j —, —CHR j — and —C(O)—;
Z is selected from the group consisting of hydrogen, alkyl and halogen;
R 8 is selected from the group consisting of hydrogen and alkyl; and
R 9 and R 10 are each individually selected from the group consisting of oxo, hydrogen and alkyl; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
13. The compound according to claim 12 , wherein the compound is selected from the group consisting of
N-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]-2-[(4-phenoxybenzyl)amino]acetamide;
2-[4-(benzyloxy)phenyl]-N-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]acetamide;
4-(1,1′-biphenyl-4-yl)-N-[1-(2-morpholin-4-ylethyl)-1H-indazol-4-yl]-4-oxobutanamide;
2-[(4-phenoxybenzyl)amino]-N-[1-(2-piperidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-(4-phenoxyphenyl)-N-[1-(2-piperidin-1-ylethyl)-1H-indazol-4-yl]acetamide;
2-[4-(benzyloxy)phenyl]-N-(1-{2-[(2R)-2-methylpiperidin-1-yl]ethyl}-1H-indazol-4-yl)acetamide;
2-[4-(benzyloxy)phenyl]-N-(1-{2-[(3R)-3-methylpiperidin-1-yl]ethyl}-1H-indazol-4-yl)acetamide;
2-(4-phenoxy-phenyl)-N-[1-(2-piperidin-1-yl-ethyl)-1H-indazol-5-yl]-acetamide;
1-(4-phenoxy-phenyl)-3-[1-(2-piperidin-1-yl-ethyl)-1H-indazol-5-yl]-urea;
N-[1-(2-morpholin-4-yl-ethyl)-1H-indazol-5-yl]-2-(4-phenoxy-phenyl)-acetamide;
1-[1-(2-morpholin-4-yl-ethyl)-1H-indazol-5-yl]-3-(4-phenoxy-phenyl)-urea;
1-{2-[5-({[(4-phenoxyphenyl)amino]carbonyl}amino)-1H-indazol-1-yl]ethyl}piperidine-4-carboxamide;
N-{1-[2-(4-methylpiperidin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-{1-[2-(3-methylpiperidin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-{1-[2-(4-methylpiperazin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-{1-[2-(2-methylpiperidin-1-yl)ethyl]-1H-indazol-5-yl}-N′-(4-phenoxyphenyl)urea;
N-{1-[2-(2-methylpiperidin-1-yl)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[2-(3-methylpiperidin-1-yl)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[2-(4-methylpiperidin-1-yl)ethyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(3-methylpiperidin-1-yl)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(4-hydroxypiperidin-1-yl)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
N-{1-[3-(4-methylpiperidin-1-yl)propyl]-1H-indazol-6-yl}-2-(4-phenoxyphenyl)acetamide;
2-(4-phenoxyphenyl)-N-[1-(3-piperidin-1-ylpropyl)-1H-indazol-6-yl]acetamide;
N-[1-(3-morpholin-4-ylpropyl)-1H-indazol-6-yl]-2-(4-phenoxyphenyl)acetamide.
14. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form a 7 membered heterocycle;
Z is selected from the group consisting of hydrogen, alkyl and halogen; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
15. The compound according to claim 1 wherein
A is —C(O)—;
B is selected from the group consisting of alkylene, alkenyl, —NR b — and —NR b alkyl;
D is a bond or is selected from the group consisting of alkylene, aryl, arylalkyl, heterocycle and heterocyclealkyl;
E is selected from the group consisting of alkyl, alkyl-C(O)—, alkyl-NH—, alkoxy, aryl-C(O)—, aryl-C═N—O—, aryl-NH—, aryloxy, aryl-S—, aryl-S-alkyl-C(O)—, arylalkyl-C(O)—, arylalkyl-NH—, arylalkoxy, cycloalkyl, cycloalkenylalkyl, heterocycle-C(O)—, heterocycle-NH—, heterocycle-O—, heterocyclealkyl-NH—, and heterocyclealkyl-O—;
R 1 is selected from the group consisting of hydrogen and alkyl;
R 2 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy;
R 3 is R c R d N—;
R 4 is selected from the group consisting of hydrogen and alkyl, or R 4 and R c taken together with any intervening atoms form a heterocycle;
each occurrence of R 5 is independently selected from the group consisting of hydrogen and alkyl;
R b is selected from the group consisting of hydrogen and alkyl, or R b and R 1 taken together with any intervening atoms form a heterocycle;
R c and R d taken together with the atoms to which they are attached form
Y is selected from the group consisting of —O—, —NR j —, —CHR j — and —C(O)—;
Z is selected from the group consisting of hydrogen, alkyl and halogen;
R 8 is selected from the group consisting of hydrogen and alkyl;
R 9 and R 10 are each individually selected from the group consisting of oxo, hydrogen and alkyl; and
m is 1, 2 or 3;
provided that:
if B is NR b — or NR b -alkyl, then
D is selected from the group consisting of alkyl, aryl, arylalkyl, heterocycle and heterocyclealkyl.
16. The compound according to claims 15 , that is
N-[1-(2-azepan-1-ylethyl)-1H-indazol-5-yl]-N′-(4-phenoxyphenyl)urea;
N-[1-(3-azepan-1-ylpropyl)-1H-indazol-6-yl]-2-(4-phenoxyphenyl)acetamide.
17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in combination with a pharmaceutically suitable carrier.
18. A method of treating obesity by inhibiting the effects of melanin concentrating hormone (MCH) through the melanin concentrating hormone receptor, comprising administrering a therapeutically effective amount of a compound of formula (I).
19. A method of treating abnormalities in reproduction and sexual behavior, thyroid hormone secretion, diuresis and water/electrolyte homeostasis, sensory processing, memory, sleeping and arousal, anxiety and depression, and seizure by inhibiting the effects of melanin concentrating hormone (MCH) through the melanin concentrating hormone receptor, comprising administrering a therapeutically effective amount of a compound of formula (I).